Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis

Kamal Menghrajani, Philip S. Boonstra, Jessica A. Mercer, Cecelia Perkins, Krisstina L. Gowin, Alissa A. Weber, Ruben Mesa, Jason R. Gotlib, Lixia Wang, Jack W. Singer, Moshe Talpaz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008 to 2016 to better understand predictors of splenic response. Response was defined as a 50% decrease in spleen size at early (3–4 months on therapy) and late (5–12 months) timepoints after therapy initiation. Early response positively correlated with higher doses of JAK inhibitor, baseline spleen size 5–10 cm, and hemoglobin. Early response negatively correlated with baseline spleen size >20 cm and high WBC. The strongest predictor of late response was whether a patient had a response at the earlier timepoint (OR 8.88). Our response models suggest that clinical factors can be used to predict which patients are more likely to respond to JAK inhibitors, and those who do not achieve an early response, i.e. within 3–4 months, should consider alternative treatments.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Spleen
Therapeutics
Hemoglobins
Survival

Keywords

  • JAK inhibitors
  • Myelofibrosis
  • myeloproliferative neoplasms
  • predictive models

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Menghrajani, K., Boonstra, P. S., Mercer, J. A., Perkins, C., Gowin, K. L., Weber, A. A., ... Talpaz, M. (Accepted/In press). Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2018.1509315

Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. / Menghrajani, Kamal; Boonstra, Philip S.; Mercer, Jessica A.; Perkins, Cecelia; Gowin, Krisstina L.; Weber, Alissa A.; Mesa, Ruben; Gotlib, Jason R.; Wang, Lixia; Singer, Jack W.; Talpaz, Moshe.

In: Leukemia and Lymphoma, 01.01.2018.

Research output: Contribution to journalArticle

Menghrajani, K, Boonstra, PS, Mercer, JA, Perkins, C, Gowin, KL, Weber, AA, Mesa, R, Gotlib, JR, Wang, L, Singer, JW & Talpaz, M 2018, 'Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis', Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2018.1509315
Menghrajani, Kamal ; Boonstra, Philip S. ; Mercer, Jessica A. ; Perkins, Cecelia ; Gowin, Krisstina L. ; Weber, Alissa A. ; Mesa, Ruben ; Gotlib, Jason R. ; Wang, Lixia ; Singer, Jack W. ; Talpaz, Moshe. / Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. In: Leukemia and Lymphoma. 2018.
@article{3d7a42c123c44e8eb41d5d3bf2d0ffba,
title = "Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis",
abstract = "JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008 to 2016 to better understand predictors of splenic response. Response was defined as a 50{\%} decrease in spleen size at early (3–4 months on therapy) and late (5–12 months) timepoints after therapy initiation. Early response positively correlated with higher doses of JAK inhibitor, baseline spleen size 5–10 cm, and hemoglobin. Early response negatively correlated with baseline spleen size >20 cm and high WBC. The strongest predictor of late response was whether a patient had a response at the earlier timepoint (OR 8.88). Our response models suggest that clinical factors can be used to predict which patients are more likely to respond to JAK inhibitors, and those who do not achieve an early response, i.e. within 3–4 months, should consider alternative treatments.",
keywords = "JAK inhibitors, Myelofibrosis, myeloproliferative neoplasms, predictive models",
author = "Kamal Menghrajani and Boonstra, {Philip S.} and Mercer, {Jessica A.} and Cecelia Perkins and Gowin, {Krisstina L.} and Weber, {Alissa A.} and Ruben Mesa and Gotlib, {Jason R.} and Lixia Wang and Singer, {Jack W.} and Moshe Talpaz",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/10428194.2018.1509315",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis

AU - Menghrajani, Kamal

AU - Boonstra, Philip S.

AU - Mercer, Jessica A.

AU - Perkins, Cecelia

AU - Gowin, Krisstina L.

AU - Weber, Alissa A.

AU - Mesa, Ruben

AU - Gotlib, Jason R.

AU - Wang, Lixia

AU - Singer, Jack W.

AU - Talpaz, Moshe

PY - 2018/1/1

Y1 - 2018/1/1

N2 - JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008 to 2016 to better understand predictors of splenic response. Response was defined as a 50% decrease in spleen size at early (3–4 months on therapy) and late (5–12 months) timepoints after therapy initiation. Early response positively correlated with higher doses of JAK inhibitor, baseline spleen size 5–10 cm, and hemoglobin. Early response negatively correlated with baseline spleen size >20 cm and high WBC. The strongest predictor of late response was whether a patient had a response at the earlier timepoint (OR 8.88). Our response models suggest that clinical factors can be used to predict which patients are more likely to respond to JAK inhibitors, and those who do not achieve an early response, i.e. within 3–4 months, should consider alternative treatments.

AB - JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008 to 2016 to better understand predictors of splenic response. Response was defined as a 50% decrease in spleen size at early (3–4 months on therapy) and late (5–12 months) timepoints after therapy initiation. Early response positively correlated with higher doses of JAK inhibitor, baseline spleen size 5–10 cm, and hemoglobin. Early response negatively correlated with baseline spleen size >20 cm and high WBC. The strongest predictor of late response was whether a patient had a response at the earlier timepoint (OR 8.88). Our response models suggest that clinical factors can be used to predict which patients are more likely to respond to JAK inhibitors, and those who do not achieve an early response, i.e. within 3–4 months, should consider alternative treatments.

KW - JAK inhibitors

KW - Myelofibrosis

KW - myeloproliferative neoplasms

KW - predictive models

UR - http://www.scopus.com/inward/record.url?scp=85053630252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053630252&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1509315

DO - 10.1080/10428194.2018.1509315

M3 - Article

C2 - 30234400

AN - SCOPUS:85053630252

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -